NeoGenomics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

NeoGenomicsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -56.1% zurückgegangen, während in der Branche Healthcare die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 10.5% pro Jahr.

Wichtige Informationen

-51.4%

Wachstumsrate der Gewinne

-50.8%

EPS-Wachstumsrate

Healthcare Wachstum der Industrie	8.5%
Wachstumsrate der Einnahmen	9.9%
Eigenkapitalrendite	-8.6%
Netto-Marge	-12.5%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

NeoGenomics: Profitability Headwinds Compress Valuation, Shares

Sep 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Sep 24

Aufschlüsselung der Einnahmen und Ausgaben

Wie NeoGenomics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqCM:NEO Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	628	-79	327	28
31 Mar 24	611	-84	321	28
31 Dec 23	592	-88	313	27
30 Sep 23	575	-96	316	27
30 Jun 23	552	-115	318	29
31 Mar 23	530	-126	312	30
31 Dec 22	510	-144	311	30
30 Sep 22	497	-163	293	32
30 Jun 22	489	-147	303	32
31 Mar 22	486	-36	291	27
31 Dec 21	484	-8	284	22
30 Sep 21	485	49	255	15
30 Jun 21	489	72	211	10
31 Mar 21	454	-11	196	9
31 Dec 20	444	4	192	8
30 Sep 20	425	-5	187	8
30 Jun 20	405	-5	184	9
31 Mar 20	419	3	182	9
31 Dec 19	409	8	175	8
30 Sep 19	378	2	164	7
30 Jun 19	343	2	147	5
31 Mar 19	309	6	134	3
31 Dec 18	277	6	114	3
30 Sep 18	262	8	103	3
30 Jun 18	252	-1	100	4
31 Mar 18	246	-9	96	4
31 Dec 17	240	-11	94	4
30 Sep 17	239	-27	98	4
30 Jun 17	241	-26	98	4
31 Mar 17	242	-29	99	4
31 Dec 16	232	-31	88	5
30 Sep 16	211	-18	85	6
30 Jun 16	175	-12	70	5
31 Mar 16	136	-7	55	5
31 Dec 15	100	-3	41	4
30 Sep 15	98	0	39	3
30 Jun 15	96	0	39	3
31 Mar 15	92	0	38	3
31 Dec 14	87	1	36	3
30 Sep 14	80	1	33	3
30 Jun 14	74	2	31	2
31 Mar 14	69	2	28	2
31 Dec 13	66	2	26	2
30 Sep 13	63	1	25	2

Qualität der Erträge: NEO ist derzeit unrentabel.

Wachsende Gewinnspanne: NEO ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: NEO ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 56.1% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von NEO verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: NEO ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Healthcare (5.8%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: NEO hat eine negative Eigenkapitalrendite (-9.12%), da es derzeit unrentabel ist.

NeoGenomics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Recent updates

Consensus EPS estimates fall by 15%

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics gets new CEO

Price target decreased to US$17.75

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer

Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022

Consensus EPS estimates fall by 21%

President & COO of Lab Operations notifies of intention to sell stock

Price target decreased to US$19.45

First quarter 2022 earnings: EPS misses analyst expectations

High number of new and inexperienced directors

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

NeoGenomics, Inc., Annual General Meeting, Jun 02, 2022